SOLID DISPERSION: AN OVERVIEW

1. Sekiguchi K., and. Obi N, "Studies on absorption of eutectic mixture" I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man," Chem. Pharm. Bull., vol. 9, 1961, pp. 866-872.
2. Chiou W. L., S. Riegelman W. L., "Pharmaceutical applications of solid dispersion systems," J. Pharm. Sci., vol. 60, no. 9, 1971, pp. 1281-1302, doi: 10.1002/jps.2600600902.
3. Brahmankar D. M., Jaiswal S. B., Biopharmaceutics and Pharmacokinetics: A Treatise, 1st ed., Delhi: Vallabh Prakashan, 1995, pp.171-172.
4. Swarbrick B., 2002. Encycolpedia of Pharmaceutical Technology, 2nd ed., vol.1, New York: Marcel Dekker Inc, pp. 641-647.
5. Leunner C, Dressman J, "Improving drug solubility for oral delivery using solid dispersions," Eur. J. Pharm. Biopharm., vol. 50, no.1, July 2000, pp. 47-60.
ISSN: 2277-8713
IJPRBS
6. Goldberg A. H., Gibaldi M., Kanig J. L., "Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures II. Experimental evaluation of eutectic mixture: Urea-acetaminophen system," J. Pharm. Sci., vol. 55, issue 5, 1966, pp. 482¬487, doi: 10.1002/jps.2600550507.
7. Amidon G. L., Lennernas H.,. Shah V. P, J. R. Crison, "A theoretical basis for biopharmaceutical drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability," Pharm. Res., vol. 12, no. 3, 1995, pp. 413¬420.
8. Prentis R. A., Lis Y., Walker S. R.,
"Pharmaceutical innovation by seven UK-owned pharmaceutical companies (1964¬1985)," Br. J. Clin. Pharmacol., vol. 25, 1988,
pp. 387-396.
9. Lipinski C. A., "Avoiding Investment in doomed drugs, is poor solubility an industry wide problem?," Curr. Drug Dis., vol. 4,
2001, pp.17-19.
10. Arunachalam A, Karthikeyan M., Konam K., Prasad P. H., Sethuraman S.,.Ashutoshkumar S, "Solid dispersions: A
Available Online At www.ijprbs.com
Review Article
Pankaj Shewale, IJPRBS, 2013; Volume 2(3): 114-143
review," Curr. Pharm. Res., vol. 1, issue 1, October- December 2010, pp. 82-90.
11. Ford J. L., "The current status of solid dispersions," Pharm. Acta Helv., vol.61,
1986, pp. 69-88.
12. Dannenfelser R., He H., Joshi Y., Bateman S., Serajuddin A. T. M., "Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycolpolysorbate 80 solid dispersion carrier system," J. Pharm. Sci.,
vol. 93, 2004, pp. 1165-1175, doi:10.1002/jps.20044.
13. Shah T. J., Amin A. F., Parikh J. R., Parikh R. H., "Process optimization and characterization of poloxamer solid dispersions of a poorly water-soluble drug," AAPS PharmSciTech., vol. 8, issue 2, Article
29, 2007, pp. E18-E24, doi: 10.1208/pt0802029.
14. Mooter G. V. D., Augustijns P., Blaton N., and Kinget R.,"Physicochemical characterization of solid dispersions of temazepam with polyethylene glycol 6000
and PVP K30," Int. J. Pharm., vol. 164, 1998, pp. 67-80, doi:10.1016/S0378-5173(97)00401-8.
ISSN: 2277-8713 IJPRBS
15. Law D., Krill S. L., Schmitt E. A., Fort J. J.,
Qiu Y., Wang W., Porter W. R., "Physicochemical considerations in the preparation of amorphous ritonavir-poly(ethylene glycol) 8000 solid dispersions," J. Pharm. Sci., vol. 90, 2001,
pp. 1015-1025, doi:10.1002/jps.1054.
16. Habib M. J., Pharmaceutical Solid Dispersion Technology, Washington: CRC,
2000, pp. 35-78.
17. Craig D. Q. M., "The mechanisms of drug release from solid dispersions in water soluble polymers," Int. J. Pharm., vol. 231, issue 2, 2002, pp. 131-144,
doi:10.1016/S0378 5173(01)00891-2.
18. S. Sethia, "Solid dispersions-revival with greater possibilities and applications in oral drug delivery," Crit. Rev. Ther. Drug Carrier Syst., vol. 20, issues 2-3, 2003, pp. 215-247.
19. Thayer A. M., "Custom manufacturer take on drug solubility issues to help pharmaceutical firms move products through development," Finding Solutions, vol. 88, no. 22, 2010, pp. 13-18.
20. Hancock, B.C., and Zogra, G., (1997). Characteristics and significance of the
Available Online At www.ijprbs.com
Review Article
Pankaj
Shewale, IJPRBS, 2013; Volume 2(3): 114-143
amorphous state in pharmaceutical systems (review). J. Pharm. Sci., 86: 1-12.
21. Dhirendra k, solid dispersions: a review, pak. j. pharm. sci., vol.22, no.2, April 2009,
pp.234-246.
22. Remingtons Pharmaceutical Sciences, 1980.vol.1 &2.
23. D.Nagasamy Venkatesh and S.Sangeetha: Solid dispersions-A review; International Journal of Pharma Research,
2008, 1, 5-12.
24. Wang X., Michel A., G. Van den Mooter, "Solid state characteristics of ternary solid ispersions composed of PVP VA64, Myrj 52 and itraconazole," Int. J. Pharm., vol. 303, issues 1-2, 2005, pp. 54-61, doi:10.1016/j.ijpharm.2005.07.002.
25. Van den Mooter G., Weuts L., Ridder T. D., Blaton N., "Evaluation of inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs," Int. J. Pharm., vol. 316, issues 1-2, 2006, pp. 1-6, doi:10.1016/j.ijpharm.2006.02.025.
26. Seth N. S., "Formulation and evaluation of solid dispersion of olanzepine,"Int. J.
ISSN: 2277-8713 IJPRBS
Pharm. Sci. Res., vol. 2, issue 3, 2011, pp.
691-697.
27. Khidr sh. Effect of block copolymers on the dissolution of some water-insoluble drugs. Part-1, nifedipine-pluronic f-127 solid dispersions system. Bull-pharm-sciassiut-univ. (bulletin-of-pharmaceuticalsciences-assiut-university) 1994;17(1):81- 86
28. Betageri GV, Makarla KR. Enhancement of Dissolution of Glyburide by Solid Dispersion and Lyophilization Techniques. International Journal of Pharmaceutics 1995
Dec; 126:155-160.
29. Kumar DS et al. Solubility improvementusing solid dispersion; strategy, mechanism and characteristics: responsiveness and prospect way outs. International Research Journal of Pharmacy,
2011, Vol. 2, p.55-60.
30. Sharma D, Soni M, Kumar S and Gupta GD. Solubility Enhancement -Eminent Role in Poorly Soluble Drugs. Research Journal of Pharmacy and Technology, 2009, Vol. 2, p.
220-224.
31. Vasconcelos TF, Sarmento B and Costa P. Solid dispersion as strategy to improve oral bioavailability of poor water soluble
Available Online At www.ijprbs.com
Review Article
Pankaj Shewale, IJPRBS, 2013; Volume 2(3): 114-143
ISSN: 2277-8713 IJPRBS
drugs. Drug Discovery Today, 2007, Vol. 12,
p. 1068-1075.
32. Kamalakkannan V, Puratchikody A, Masilamani K and Senthilnathan B, Solubility enhancement of poorly soluble drugs by solid dispersion technique - A review. Journal of Pharmacy Research,
2010, Vol. 3, p. 2314-2321.
33. Liu R. Water-Insoluble drug formulation. New York: CRC Press. 2nd ed. 2008; 522.
34. Vasconcelos T, Sarmanto B, Costa P. Solid dispersion as strategy to improve oral bioavailability of poorly water soluble
drugs. J Pharm Sci. 2007; 12:1068-1075.
35. Chiou WL, Riegelman S. Preparation and dissolution characteristics of several fastrelease solid dispersion of griseofulvin. J
Pharm Sci. 1969; 55:1505-1510.
36. Kanig JL. Properties of fused mannitol in compressed tablets. J Pharm Sci. 1964;
53:188-192.
37. Walker SE, Gangley JA, Bedford K, Eaves T. The filling of molten and thyrotrophic formulations into hard gelatin capsule. J Pharm Pharmacol. 1980; 32:389-393.
38. Vadnere MK. Co-precipitates and Melts. In: Swarbrick J, Boylan JC, editors. Encyclopedia of pharmaceutical technology. New York: Marcel Dekker Inc; 1990.
39. Sharma DK, Joshi SB. Solubility enhancement strategies for poorly water soluble drug in solid dispersion: A Review. Asian Journal of Pharmaceutics. 2007; 1:9¬19.
40. Ambike AA, Mahadik KR, Paradkar A. Spraydried amorphous solid dispersions of simvastatin, a low Tg drug: In vitro and invivo evaluations. Pharm Res. 2005;
22:990¬41. 998.
42. Takayama K, Nambu N, Nakai T. Factor affecting the dissolution of ketoprofen from solid disoersion in various water solublepolymers. Chem Pharm Bull. 1982;
30:673-677.
43. Subramanian B, Rajewski RA, Snavely K. Pharmaceutical processing with supercritical carbon dioxide. J Pharm Sci.
1997; 86:885- 890.
44. Palakodaty S, York P. Phase behavioural effects on particle formation process using
Available Online At www.ijprbs.com
Review Article
Pankaj Shewale, IJPRBS, 2013; Volume 2(3): 114-143
supercritical fluids. Pharm Res. 1999;
16:976-985.
45. Sethia SE, Squillante. Physicochemicalcharacterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method. J
Pharm Sci. 2002; 91:1948-1957.
46. Vemavarapu C, Mollan MJ, Needham TE. Crystal doping aided by rapid expansion of supercritical solutions. AAPS Pharm Sci Tec. 2002; 13:1-15.
47. Muhrer GU, Meier F, Fusaro S, Mazzotti M. Use of compressed gas precipitation to enhance the dissolution behavior of a poorly water-soluble drug: Generation of drug microparticles and drug-polymer solid dispersion. Int J Pham. 2006; 308:69-83.
48. Jarmer DJ, Lengsfeld CS, Anseth KS, Randolph TW. Supercritical fluid crystallization of griseofulvin: Crystal habit modification with a selective growth
inhibitor. Pharm Sci. 2005; 94:2688-2702.
49. Edwards AD, Shekunov BY, Kordikowski A, Forbes RT, York P. Crystallization of pure anhydrous polymorphs of carbamezapine by solution enhanced dispersion with
ISSN: 2277-8713
IJPRBS
supercritical fluids (SEDS). J Pharm Sci.
2001; 90:1115-1124.
50. Morita M, Hisrota S. Correlation studies between thermal and dissolution rate constant of cimitidine drug and tablet.
Chem Pharm Bull. 1985; 33:2091.
51. Shine SC, Oh IJ, Lee YB, Choi HK, Choi JS. Enhancement dissolution of furosemide by co-precipitating or co-grinding with corsprovidone. Int J Pharm. 1998; 175:17¬24.
52. Breitenbach J. Melt extrusion: Fromprocess to drug delivery technology. Pharm Biopharm. 2002; 54:107-117.
53. Choksi R, Zia H. Hot-melt extrusion technique: A review. J Pharm Res 2004;
3:107-117.
54. Breitenbach JW, Confocal J. Raman spectroscopy: Analytical approach to solid dispersion and mapping of drug. Pharm Res.
1999; 16:1109-1113.
55. Verreck G, Six K, Van G, Mooter L, Baert J, Brewster ME. Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by
Available Online At www.ijprbs.com
Review Article
Pankaj
Shewale, IJPRBS, 2013; Volume 2(3): 114-143
melt extrusion. Int J Pharm. 2003; 251:165¬174.
56. Breitenbach J, Soliq A. Melt extrusion: from process to drug delivery technology.
Eur J Pharm. 2002; 54:107-117.
57.
Susham
a R, Desai MS, Loyd V, Robert B, Greenwood ML. Effervescent solid dispersions of prednisone, griseofulvin and primidone. Drug Dev Ind Pharm. 1989;
15:671-677.
58. Ho HO, Shu HL, Tsai T, Sheu MT. The
preparation and characterization of solid dispersions on pellets using a fluidized bed system. Int J Pharm. 1996; 139:223-229.
59. Yamamoto K, Nakamo M, Arita T, Nakai Y. Preparation and thermal characterization
o
f poly (ethyl oxide)/ griseofulvin solid dispersions for biomedical application. J Pharmaco Biopharm. 1974; 2:487-495.
60. Kaushal, A.M, Guptam P., and Bansal, AK., 2004.Amorphous drug delivery systems: molecular aspects, design, and performance. Crit. Rev. There. Drug Carrier Syst., 21(3): 133-193.
61. Taylor, L.S., and Zografi, G., 1997. Spectroscopic characterization of
ISSN: 2277-8713 IJPRBS
interactions between PVP and indomethacin in amorphous molecular dispersions. Pharmaceut. Res., 14: 1691¬1698.
62. Buckton, G., and Darcy, P., 1995. The use of gravimetric studies to assess the degree of crystallinity of predominantly crystalline powders. Int. J. Pharmaceut.,
123: 265-271.
63. Sebhatu, T., Angberg, M., and Ahlneck, C., 1995. Assessment of the degree of disorder in crystalline solids by isothermal microcalorimetry. Int, J. Pharmaceut.,104:
135-144.
64. Pikal, M.J., Lukes, A.L., Lang, J.E., and Gaines, K., 1978. Quantitative crystallinity determinations for beta-lactam antibiotics by solution calorimetry: correlations with stability. J. Pharmaceut. Sci., 67(6): 767-73.
65. Kerc, J., and Srcic, S., 1995. Thermal analysis of glassy pharmaceuticals. Thermochim. Acta., 248: 81-95.
66. Demeuter, P., Rahier, H., and Van Mele, B., 1999. The use of modulated temperature differential scanning calorimetry for the characterisation of food systems. Int. J. Pharmaceut., 192(1): 77-84.
Available Online At www.ijprbs.com
Review Article
Pankaj Shewale, IJPRBS, 2013; Volume 2(3): 114-143
67. Cilurzo, F., Minghetti, P., Casiraghi, A., and Montanari, L., 2002. Characterization of nifedipine solid dispersions. Int. J. Pharmaceut., 242(1-2): 313-317.
68.
Vasanthavada
, M., Tong, W.Q., Joshi, Y., and Kislalioglu, M.S., 2004. Phase behavior
ISSN: 2277-8713 IJPRBS
of amorphous molecular dispersions I: Determination of the degree and mechanism of solid solubility. Pharmaceut. Res., 21(9): 1598-1606.